

RESEARCH MONOGRAPH . COMPOUND PROFILE

Centrophenoxine

A synthetic ester of dimethylaminoethanol and para-chlorophenoxyacetic acid developed in 1959 at the French National Scientific Research Center, distinguished from other cholinergic precursors by its capacity to reduce neuronal lipofuscin accumulation and to enhance phospholipid membrane turnover in aging brain tissue.

DOCUMENT	KDC-MN-1445
ISSUED	2026-05-11
REVISION	1.0
AUTHOR	Kodiac bioLabs Research
COMPOUND CLASS	Cholinergic precursor ester combining dimethylaminoethanol and 4-chlorophenoxyacetic acid with lipofuscin-clearing and neuroprotective activity

RESEARCH USE ONLY

ABSTRACT

Centrophenoxine (meclofenoxate, Lucidril; 2-(dimethylamino)ethyl (4-chlorophenoxy)acetate; CAS 51-68-3; molecular formula $C_{12}H_{16}ClNO_3$; molecular weight 257.71 g/mol) is a synthetic cholinergic precursor and neuroprotective agent developed in 1959 at the Centre National de la Recherche Scientifique (CNRS) in France. The compound is an ester of two biologically active moieties: dimethylaminoethanol (DMAE), a naturally occurring aminoalcohol found in small quantities in the human brain and implicated in choline and phospholipid metabolism, and para-chlorophenoxyacetic acid (pCPA), a synthetic auxin derivative that serves as a lipophilic carrier facilitating blood-brain barrier penetration and extending the biological half-life of the DMAE component. Following oral administration, centrophenoxine undergoes rapid hepatic ester hydrolysis to release DMAE and pCPA. The DMAE moiety is subsequently methylated to choline, which enters the acetylcholine synthetic pathway and is incorporated into membrane phospholipids as phosphatidyl dimethylaminoethanol and phosphatidylcholine. The compound's most distinctive pharmacological feature is the reduction of lipofuscin, the heterogeneous age pigment that accumulates progressively in postmitotic cells including cortical and hippocampal neurons, cardiac myocytes, and retinal pigment epithelium. The lipofuscin-clearing activity was first demonstrated by Nandy and Bourne in 1966 in senile guinea pig neurons and has been replicated across multiple rodent species, with reductions of 25 to 40 percent in cortical and hippocampal lipofuscin content following chronic oral administration at doses of 40 to 80 mg/kg/day for three to six

months [1, 2]. The mechanism of lipofuscin clearance is incompletely characterized but is attributed to a combination of enhanced lysosomal enzyme activity, increased membrane phospholipid turnover (which dilutes the lipofuscin granule burden through membrane remodeling), and direct free radical scavenging by the DMAE moiety, which is incorporated into neuronal membranes as phosphatidyl-DMAE and functions as a hydroxyl radical scavenger [3, 4]. The clinical evidence base in human cognitive impairment spans approximately five decades but is modest in scale and quality by contemporary standards. The largest double-blind, randomized, placebo-controlled trial in healthy elderly subjects (Marcer and Hopkins, 1977; n = 50) demonstrated significant improvement in delayed free recall after three months of oral centrophenoxine at 600 mg twice daily, with no effect on immediate recall, digit span, or recognition memory, suggesting a selective enhancement of memory consolidation into long-term storage [5]. A second double-blind trial in 50 patients with organic dementia (Pek and Fulop, 1983) reported improvement in 48 percent of centrophenoxine-treated subjects versus 28 percent on placebo, although with high variability and methodological limitations [6]. Smaller open-label and controlled studies have reported improvements in vigilance, reaction time, and subjective mental alertness in elderly populations. The compound is marketed as a prescription medicine in several European countries (France, Germany, Hungary, Austria), in Japan, and in parts of Latin America for indications including senile cognitive impairment, post-stroke cognitive rehabilitation, and alcohol-related cognitive decline. It is not approved by the United States Food and Drug Administration and is sold as a research chemical in the United States. Pharmacokinetics are characterized by rapid oral absorption, rapid hepatic ester

hydrolysis (plasma half-life of the parent ester is approximately 30 to 60 minutes), and a longer effective duration attributable to the persistence of the DMAE metabolite in brain tissue. Typical clinical doses range from 600 to 2000 mg per day in two or three divided administrations. The adverse-event profile is favorable; the most commonly reported effects are mild gastrointestinal discomfort, insomnia, and headache, generally at higher doses and resolving with dose reduction. This monograph reviews the chemistry, synthesis, and structural pharmacology of centrophenoxine; the lipofuscin-clearing, cholinergic, antioxidant, and membrane-modifying mechanisms; the pharmacokinetic profile; the preclinical and clinical evidence base; sourcing and quality verification; reconstitution and handling; stack interactions with racetams and other cholinergic agents; the adverse-event and safety profile; and a comparative assessment of five cholinergic and neuroprotective alternatives (alpha-GPC, citicoline, DMAE, piracetam, and idebenone) against centrophenoxine on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Meclofenoxate.

Common name: Centrophenoxine. The name centrophenoxine is used interchangeably with meclofenoxate in the research literature and is the more common designation in the nootropic and research-chemical marketplace.

Marketed names: Lucidril (the original brand, introduced by Laboratoires Lucien in France and subsequently licensed to various manufacturers), Cerutil (generic markets in Latin America), Helfergin (Germany and Austria), Marucotol (Japan).

Chemical Abstracts Service registry numbers: 51-68-3 (free base), 3685-84-5 (hydrochloride salt). The hydrochloride salt is the standard formulated and commercially supplied form.

International Union of Pure and Applied Chemistry name: 2-(dimethylamino)ethyl 2-(4-chlorophenoxy)acetate. The compound is the ester of 2-(dimethylamino)ethanol (DMAE, deanol) and (4-chlorophenoxy)acetic acid (pCPA, a synthetic plant auxin analog).

PubChem CID: 4039.

DrugBank ID: DB13758.

1.2 Structural class and chemistry

Centrophenoxine is an aminoethanol ester. The structural class places it among the cholinergic precursor esters, a small group of compounds designed to deliver DMAE or choline to the central nervous system through ester-bond-mediated pro-drug strategies. The compound consists of two pharmacologically relevant fragments joined by a carboxylate ester bond: the DMAE fragment (2-(dimethylamino)ethanol) contributes cholinergic and phospholipid-modifying ac-

tivity, while the pCPA fragment (4-chlorophenoxyacetic acid) contributes lipophilicity that enhances gastrointestinal absorption and blood-brain barrier penetration relative to free DMAE [7].

Molecular formula: C₁₂H₁₆ClNO₃ (free base); C₁₂H₁₇Cl₂NO₃ (hydrochloride salt).

Exact mass: 257.0819 g/mol (free base, monoisotopic).

Molecular weight: 257.71 g/mol (free base); 294.17 g/mol (hydrochloride salt).

Physical properties: White to off-white crystalline powder (as the hydrochloride salt). Freely soluble in water, soluble in methanol and ethanol, sparingly soluble in nonpolar organic solvents. The free base is a colorless to pale yellow liquid at room temperature. Melting point of the hydrochloride salt is approximately 138 to 141 degrees Celsius.

Stereochemistry: Centrophenoxine contains no stereocenters. The molecule is achiral. There is no enantiomeric consideration in sourcing or quality verification.

Structural note on the pCPA moiety: The 4-chlorophenoxyacetic acid fragment is structurally related to the synthetic auxin 2,4-dichlorophenoxyacetic acid (2,4-D), a herbicidal agent. The monochlorinated pCPA moiety released upon hydrolysis of centrophenoxine does not possess herbicidal activity at physiological concentrations and is cleared by renal excretion as a glucuronide conjugate. Nevertheless, some early literature raised theoretical concerns about the auxin-like fragment, which have not been substantiated in six decades of clinical use [8].

1.3 Synthesis

The synthesis of centrophenoxine is a single-step esterification. 4-Chlorophenoxyacetic acid is activated (typically with thionyl chloride to form the acid chloride, or with a carbodiimide coupling reagent) and reacted with 2-(dimethylamino)ethanol in an anhydrous organic solvent (dichloromethane, tetrahydrofuran, or toluene) [9]. The product is isolated by extraction, washed with aqueous base to remove unreacted acid, and converted to the hydrochloride salt by treatment with hydrogen chloride in diethyl ether or isopropanol. Recrystallization from ethanol or ethanol-diethyl ether mixtures yields pharmaceutical-grade material at greater than 99 percent purity. The synthesis is straightforward, high-yielding (typically 85 to 95 percent), and amenable to multi-kilogram production. The

absence of stereocenters eliminates the need for chiral resolution or asymmetric synthesis. Industrial manufacturing costs are low, reflected in the moderate pricing of the compound in both pharmaceutical and research-chemical markets.

2. Abstract

Centrophenoxine (meclofenoxate, Lucidril) is a synthetic cholinergic precursor ester developed in 1959 at the Centre National de la Recherche Scientifique (CNRS) in France as a treatment for age-related cognitive decline. The compound combines two biologically active moieties through an ester bond: dimethylaminoethanol (DMAE), a choline precursor and membrane phospholipid modifier, and parachlorophenoxyacetic acid (pCPA), a lipophilic carrier that enhances oral absorption and blood-brain barrier penetration. Following oral administration and rapid hepatic hydrolysis, the released DMAE contributes to cholinergic neurotransmission through methylation to choline and subsequent acetylcholine synthesis, and to membrane remodeling through incorporation into neuronal phospholipids as phosphatidyl-DMAE [3, 10].

The compound's signature pharmacological activity is the reduction of lipofuscin, the heterogeneous intracellular age pigment composed of oxidatively cross-linked proteins and lipids that accumulates in postmitotic neurons with advancing age. Nandy and Bourne first demonstrated this activity in 1966 in guinea pig cortical neurons [1], and the finding has been replicated across multiple species (guinea pig, rat, mouse) and brain regions (cerebral cortex, hippocampus) with consistent reductions of 25 to 40 percent after chronic treatment [2, 11, 12]. The lipofuscin-clearing mechanism is attributed to enhanced lysosomal turnover, increased membrane phospholipid remodeling, and direct antioxidant activity of the phosphatidyl-DMAE incorporated into neuronal membranes [4].

Additional pharmacological activities include enhancement of cerebral glucose and oxygen uptake, stimulation of RNA and protein synthesis in neuronal and glial cells, upregulation of endogenous antioxidant enzymes (superoxide dismutase, catalase, glutathione reductase), and direct scavenging of hydroxyl and lipid peroxyl radicals [3, 13, 14]. These activities collectively support a neuroprotective profile that extends beyond simple cholinergic precursor supplementation.

The clinical evidence base spans five decades but is modest by contemporary standards. The principal controlled trials (Marcer and Hopkins, 1977; Pek and Fulop, 1983; Fulop et al., 1990) have reported selective improvements in long-term memory consolidation, vigilance, and subjective mental alertness in elderly sub-

jects, with effect sizes in the small-to-moderate range [5, 6, 15]. The compound is marketed as a prescription medicine for senile cognitive impairment in France, Germany, Hungary, Austria, Japan, and several other jurisdictions. It is not approved by the United States Food and Drug Administration.

Pharmacokinetics are dominated by rapid hepatic ester hydrolysis, with a parent-compound plasma half-life of approximately 30 to 60 minutes and a longer effective duration attributable to DMAE tissue persistence. Typical therapeutic doses are 600 to 2000 mg per day in divided administrations. The adverse-event profile is favorable, dominated by mild gastrointestinal discomfort and insomnia at higher doses. The compound is contraindicated in pregnancy owing to the teratogenic potential of the DMAE moiety observed in animal studies.

3. Discovery and Development History

3.1 Origin

Centrophenoxine was synthesized in 1959 at the Centre National de la Recherche Scientifique (CNRS) in France by a team led by researchers investigating prodrug strategies for delivering DMAE to the central nervous system. DMAE (deanol, 2-dimethylaminoethanol) had been recognized since the 1950s as a cholinergic precursor with potential application in cognitive decline and movement disorders, but its poor blood-brain barrier penetration and rapid peripheral metabolism limited its therapeutic utility. The CNRS team esterified DMAE with pCPA to produce a lipophilic prodrug that could be absorbed orally and hydrolyzed in the liver and brain to release DMAE at therapeutically relevant concentrations [7, 8].

3.2 Early clinical introduction

The compound was introduced to the European pharmaceutical market under the brand name Lucidril in the early 1960s for indications including senile cognitive impairment, post-stroke cognitive rehabilitation, and age-related memory decline. Registration was granted in France, Germany (as Helfergin), Hungary, Austria, Italy, and subsequently in Japan and several Latin American countries. The indications and marketing approvals predated the modern regulatory framework for cognitive drugs and were based on the clinical evidence standards of the era, which did not require large-scale randomized controlled trials of the type now mandated by the European Medicines Agency or the United States Food and Drug Administration.

3.3 Lipofuscin research era

The most scientifically significant chapter in centrophenoxine's development history began with the Nandy and Bourne (1966) demonstration that chronic centrophenoxine administration reduced lipofuscin content in cortical neurons of senile guinea pigs [1]. This finding stimulated a productive research program spanning the 1960s through 1980s. Nandy (1968) published extended studies confirming and quantifying the lipofuscin reduction [2]. Riga and Riga (1974) demonstrated the ef-

fect in aged rat cortical and cerebellar neurons [11]. Spoerri and Glees (1974) reported lipofuscin reduction in aged rat hippocampal neurons after five months of oral treatment [12]. Patro et al. (1992) confirmed the lipofuscin-clearing activity in the retinal pigment epithelium and frontal cortex of aged rats [16].

The lipofuscin research positioned centrophenoxine as a potential anti-aging compound and attracted attention from the biogerontology community. The "disposable soma" and "free radical" theories of aging both predicted that accumulation of damaged intracellular material (including lipofuscin) would impair cellular function; centrophenoxine was one of the first pharmacological interventions demonstrated to partially reverse this accumulation in postmitotic neurons. The finding remains the compound's most distinctive contribution to neuropharmacology.

3.4 Clinical trial period

The principal clinical trials of centrophenoxine were conducted between the early 1970s and the early 1990s. Gedye, Exton-Smith, and Wedgwood (1972) conducted one of the first small-scale double-blind studies demonstrating cognitive improvement in elderly patients with organic dementia [17]. Marcer and Hopkins (1977) conducted the best-designed trial of the era: a double-blind, randomized, placebo-controlled study in 50 healthy elderly subjects demonstrating selective improvement in delayed free recall after three months of treatment at 600 mg twice daily [5]. Pek and Fulop (1983) extended the findings to dementia patients [6]. Fulop et al. (1990) reported improvements in cognitive measures in a cohort of 74 healthy elderly subjects over nine months [15].

3.5 Contemporary status

Centrophenoxine remains a marketed medicine in several European and Asian jurisdictions but has not been the subject of a large-scale randomized controlled trial meeting contemporary regulatory standards (Phase 3, multicenter, adequately powered). The compound is used extensively in the nootropic research community and is sold as a research chemical in the United States and other jurisdictions where it lacks pharmaceutical registration. A 2022 publication by Dolan et al. in *Clinical Toxicology* documented the presence of centrophenoxine as an unapproved drug in cognitive enhancement dietary supplements sold in the United States, raising regulatory concerns about uncontrolled consumer exposure [18].

4. Molecular Pharmacology

Centrophenoxine exerts its pharmacological effects through multiple interconnected mechanisms that derive from both the intact parent molecule and its two hydrolysis products. The composite pharmacology encompasses cholinergic precursor activity, membrane phospholipid modification, lipofuscin clearance, antioxidant activity, and enhancement of cerebral energy metabolism.

4.1 Cholinergic precursor mechanism

The DMAE released by hepatic and neural hydrolysis of centrophenoxine is a substrate for choline kinase and for the sequential methylation pathway that converts DMAE to choline. Choline is the immediate precursor for acetylcholine synthesis by choline acetyltransferase in cholinergic nerve terminals. By increasing the availability of choline, centrophenoxine indirectly supports acetylcholine production, particularly under conditions of increased cholinergic demand (aging, neurodegenerative disease, concurrent racetam use) [10].

The cholinergic precursor activity of centrophenoxine is less direct than that of alpha-glycerylphosphorylcholine (alpha-GPC) or cytidine diphosphate-choline (citicoline), both of which deliver choline directly. The DMAE-to-choline conversion requires enzymatic methylation and is subject to rate-limiting constraints; consequently, centrophenoxine is not considered a high-potency cholinergic precursor. The advantage of centrophenoxine over free DMAE is the enhanced blood-brain barrier penetration conferred by the pCPA ester linkage, resulting in higher central DMAE concentrations per unit oral dose [7].

4.2 Membrane phospholipid modification

DMAE is incorporated directly into neuronal membrane phospholipids as phosphatidyl-DMAE (phosphatidyl dimethylethanolamine, PDME), partially substituting for phosphatidylcholine and phosphatidylethanolamine in the membrane bilayer [3, 10]. The incorporation of phosphatidyl-DMAE modifies membrane biophysical properties, including fluidity and permeability. In aged neurons, membrane rigidity increases due to lipid peroxidation, cholesterol accumulation, and lipofuscin de-

position; the incorporation of phosphatidyl-DMAE may partially reverse this rigidity by introducing a structurally distinct phospholipid that resists oxidative cross-linking.

The membrane incorporation also provides the structural basis for the antioxidant activity of phosphatidyl-DMAE, which functions as an intramembrane hydroxyl radical scavenger (section 4.4).

4.3 Lipofuscin clearance

Lipofuscin is a heterogeneous aggregate of oxidatively modified proteins, lipids, and metal ions that accumulates in the lysosomes of postmitotic cells. In neurons, lipofuscin accumulation correlates with age and is hypothesized to impair lysosomal function, autophagic capacity, and overall cellular proteostasis. The centrophenoxine-mediated reduction of lipofuscin was first demonstrated by Nandy and Bourne (1966) and has been replicated across multiple laboratories and species [1, 2, 11, 12, 16].

The mechanism of lipofuscin clearance is not fully elucidated. Three contributing pathways have been proposed: (a) enhancement of lysosomal enzyme activity, permitting more efficient degradation of the lipofuscin aggregate; (b) increased membrane phospholipid turnover, which dilutes the lipofuscin burden as new membrane material replaces old; and (c) reduction of the oxidative processes that generate lipofuscin precursors, through both direct free radical scavenging and up-regulation of endogenous antioxidant enzymes [4, 14].

Quantitative studies in aged rats have demonstrated reductions of 25 to 40 percent in cortical neuronal lipofuscin content after three to six months of oral centrophenoxine at 40 to 80 mg/kg/day [2, 12]. The effect is progressive with treatment duration and partially reverses upon treatment cessation, suggesting that ongoing oxidative lipofuscin generation resumes when antioxidant and membrane-remodeling support is withdrawn.

4.4 Antioxidant activity

Centrophenoxine and its DMAE metabolite exhibit antioxidant activity through multiple pathways. Phosphatidyl-DMAE incorporated into neuronal membranes scavenges hydroxyl radicals with high efficiency, providing an intramembrane an-

tioxidant defense that supplements the cytosolic glutathione system and the mitochondrial manganese superoxide dismutase system [3, 4].

In addition to direct radical scavenging, chronic centrophenoxine administration upregulates the activity of endogenous antioxidant enzymes in brain tissue. Studies in aged rats have demonstrated increases in superoxide dismutase, catalase, and glutathione reductase activity in cerebral cortex and hippocampus following chronic oral treatment [13, 14]. Lipid peroxidation markers (malondialdehyde, 4-hydroxynonenal) are correspondingly reduced.

In a chronic cerebral hypoperfusion model in rats, meclofenoxate treatment reduced hippocampal lipid peroxidation, lowered hydroxyl radical levels, and improved spatial memory performance, supporting the functional relevance of the antioxidant mechanism to cognitive outcomes [19].

4.5 Cerebral energy metabolism

Centrophenoxine increases cerebral glucose uptake and oxygen consumption in aged animals, an effect attributed to both the cholinergic precursor activity (acetylcholine stimulates regional cerebral blood flow) and a direct metabolic stimulatory effect that may involve enhanced glucose transporter expression or activity [14, 20]. The compound also stimulates RNA and protein synthesis in both neuronal and glial cells, findings that are consistent with a generalized enhancement of anabolic processes in brain tissue [20].

5. Pharmacokinetics

5.1 Absorption

Centrophenoxine is well absorbed from the gastrointestinal tract after oral administration. The pCPA moiety confers lipophilicity that enhances intestinal absorption relative to free DMAE, which is a hydrophilic small molecule with limited passive transcellular absorption. Time to peak plasma concentration of the intact parent ester is approximately 30 to 60 minutes after oral dosing in fasted subjects. Food modestly delays absorption without significantly affecting overall exposure [7, 8].

The compound crosses the blood-brain barrier in its intact ester form, and hydrolysis to DMAE and pCPA also occurs within the central nervous system. The dual-site hydrolysis (hepatic and neural) ensures that a portion of the administered dose reaches brain tissue as the intact ester, where local hydrolysis releases DMAE directly at the site of action.

5.2 Distribution

The volume of distribution has not been precisely characterized in formal pharmacokinetic studies. The lipophilicity of the intact ester predicts moderate tissue partitioning. DMAE, once released, distributes broadly to brain, liver, and kidney. Central nervous system penetration is confirmed by the pharmacological effects (cholinergic, lipofuscin-clearing, and electroencephalographic) observed after oral dosing.

5.3 Metabolism

Centrophenoxine undergoes rapid ester hydrolysis by hepatic and tissue esterases, yielding DMAE and pCPA. This hydrolysis is the dominant metabolic transformation and is responsible for the short plasma half-life of the parent compound (approximately 30 to 60 minutes).

DMAE is subsequently metabolized by sequential methylation to monomethylethanolamine and then to choline, catalyzed by methyltransferase enzymes using S-adenosylmethionine as the methyl donor. Choline enters the acetyl-

choline synthetic pathway or is incorporated into membrane phospholipids via the Kennedy pathway (CDP-choline pathway). A portion of DMAE is directly incorporated into membrane phospholipids as phosphatidyl-DMAE without prior methylation to choline [3, 10].

pCPA is conjugated with glucuronic acid in the liver and excreted in urine as the glucuronide conjugate. The pCPA metabolite does not accumulate with chronic dosing at therapeutic doses.

5.4 Elimination

The plasma half-life of the intact parent ester is approximately 30 to 60 minutes, reflecting rapid hepatic hydrolysis. The effective duration of pharmacological activity is substantially longer than the parent-compound half-life, attributable to the persistence of DMAE in brain tissue and the slow turnover of phosphatidyl-DMAE incorporated into neuronal membranes. The DMAE metabolite has been reported to have a tissue half-life substantially exceeding that of the parent compound, although precise human pharmacokinetic data for the DMAE moiety following centrophenoxine dosing are limited.

Renal excretion accounts for the majority of elimination, principally as pCPA glucuronide, choline metabolites, and trace amounts of unchanged drug. Hepatic impairment would be expected to prolong exposure by reducing esterase-mediated hydrolysis, although formal studies in hepatically impaired populations have not been published.

5.5 Routes of administration

The principal route is oral administration. Capsule and tablet formulations of 250 mg to 500 mg (as the hydrochloride salt) are available in marketed pharmaceutical preparations and in research-chemical form. Parenteral (intramuscular or intravenous) administration has been described in early clinical literature but is not standard practice. The compound dissolves readily in aqueous solution as the hydrochloride salt and is amenable to intravenous infusion for research applications.

5.6 Special populations

Pediatric pharmacokinetics have not been formally characterized. The compound is not indicated for pediatric use. Geriatric pharmacokinetics may differ from younger adults due to age-related decline in hepatic esterase activity, potentially prolonging the parent-compound half-life modestly; this has not been formally studied. Pregnancy is a contraindication owing to the teratogenic potential of DMAE in animal studies.

6. Preclinical Pharmacology

6.1 Lipofuscin clearance studies

The preclinical literature on centrophenoxine is dominated by lipofuscin studies. Nandy and Bourne (1966) first reported that chronic centrophenoxine administration to senile guinea pigs (18 to 24 months of age) reduced the lipofuscin content of cortical neurons by approximately 30 to 40 percent compared to age-matched controls after treatment periods of three to five months [1]. Nandy (1968) extended these findings and provided quantitative morphometric analysis of lipofuscin granule area in treated versus control neurons [2].

Riga and Riga (1974) replicated the lipofuscin-clearing activity in aged Wistar rats, demonstrating reductions in cortical and cerebellar neuronal lipofuscin after oral centrophenoxine at 40 mg/kg/day for six months [11]. Spoerri and Glees (1974) confirmed the effect in hippocampal neurons of aged rats after five months of treatment [12]. Patro et al. (1992) extended the findings to the retinal pigment epithelium, demonstrating that centrophenoxine reduced lipofuscin accumulation in both retinal and frontal cortex tissues of aged rats [16].

A notable negative finding was reported by Katz et al. (1983), who observed that centrophenoxine treatment in young and middle-aged mice did not prevent lipofuscin accumulation when treatment was initiated before substantial lipofuscin had accumulated, suggesting that the compound acts primarily on existing lipofuscin deposits rather than preventing de novo formation [21].

6.2 Antioxidant and neuroprotection studies

Chronic centrophenoxine administration in aged rats increases the activity of superoxide dismutase, catalase, and glutathione reductase in cerebral cortex and hippocampus [13, 14]. Lipid peroxidation markers are correspondingly reduced. In a chronic cerebral hypoperfusion model in rats (permanent bilateral common carotid artery occlusion), meclofenoxate treatment at 100 mg/kg/day for eight weeks reduced hippocampal malondialdehyde levels, lowered hydroxyl radical concentrations, and improved performance in the Morris water maze, demonstrating functional cognitive benefit linked to oxidative stress reduction [19].

6.3 Electrophysiological and neurochemical studies

Comparative electrophysiological studies of centrophenoxine and piracetam have demonstrated that both compounds increase the amplitude of transcranial evoked potential (TEP) components and stabilize the dominant peak in EEG power spectrum distribution, consistent with improved cortical arousal and information processing [22]. Centrophenoxine increases whole-brain acetylcholine content in rodents, though to a lesser degree than direct choline supplementation, consistent with its indirect cholinergic precursor mechanism [10].

6.4 RNA and protein synthesis

Early studies by Nandy and colleagues demonstrated that centrophenoxine stimulates RNA synthesis in neuronal and glial cell cultures, an effect quantified by increased incorporation of tritiated uridine. Protein synthesis, measured by leucine incorporation, is similarly enhanced. These findings support a generalized anabolic effect on brain tissue that may contribute to the neuroprotective profile independently of the cholinergic and antioxidant mechanisms [20].

7. Clinical Evidence Base

7.1 Healthy elderly subjects

The Marcer and Hopkins (1977) study is the best-designed and most frequently cited clinical trial of centrophenoxine [5]. Fifty healthy elderly subjects (ages 65 to 80 years) were randomized to centrophenoxine 600 mg twice daily or placebo for three months in a double-blind parallel-group design. The primary outcome measures were a battery of memory tests including immediate free recall, delayed free recall, digit span, recognition memory, and subjective mental alertness ratings.

The centrophenoxine group showed statistically significant improvement in delayed free recall compared to placebo ($p < 0.01$), with no significant differences in immediate free recall, digit span, or recognition memory. The authors interpreted this pattern as evidence that centrophenoxine selectively enhances the consolidation of new information into long-term memory without affecting short-term memory capacity or retrieval. Additionally, a significantly greater proportion of centrophenoxine-treated subjects reported increased subjective mental alertness compared to placebo.

Fulop et al. (1990) conducted a nine-month double-blind, randomized, placebo-controlled trial in 74 healthy elderly subjects treated with centrophenoxine 600 mg twice daily [15]. The centrophenoxine group showed significant improvement in memory consolidation consistent with the Marcer and Hopkins findings. Effect sizes were in the small-to-moderate range.

7.2 Dementia patients

Gedye, Exton-Smith, and Wedgwood (1972) conducted an early small-scale double-blind study in elderly patients with organic dementia, reporting that the treated group showed measurable cognitive improvement relative to matched controls [17].

Pek and Fulop (1983) conducted a double-blind, randomized, placebo-controlled trial in 50 patients with organic dementia, treated with centrophenoxine 2 g/day or placebo for eight weeks [6]. Intra-individual analyses showed that 48 percent of the

centrophenoxine group (10 of 21 evaluable) displayed improvements in memory function measures compared to 28 percent (7 of 25) in the placebo group. The study was limited by high inter-individual variability and a small sample size.

An open-label study by Dastoor and Cole (1980) in 63 patients with mild-to-moderate Alzheimer's disease reported that toxicity was "very low" and that the compound was generally well tolerated, though the cognitive outcome measures were not reported with sufficient statistical rigor to draw firm efficacy conclusions [23].

7.3 Cerebrovascular and post-stroke indications

The compound has been studied in post-stroke cognitive rehabilitation in several small European trials. The evidence is limited and largely observational. The compound is registered in some jurisdictions for this indication based on the pre-modern regulatory evidence standards applicable at the time of original registration.

7.4 Limitations of the clinical evidence

The clinical evidence base for centrophenoxine is modest by contemporary standards. No trial has exceeded 100 subjects. No trial has been conducted to contemporary Phase 3 standards (multicenter, adequately powered, intention-to-treat analysis, validated cognitive endpoint batteries). The positive trials are consistent in demonstrating a small-to-moderate effect on memory consolidation in elderly subjects, but the evidence is insufficient to establish centrophenoxine as an evidence-based treatment for any specific cognitive disorder by current regulatory criteria. The compound's continued pharmaceutical registration in several jurisdictions reflects historical approval rather than contemporary evidence-based evaluation.

8. Sourcing and Quality Verification

Pharmaceutical-grade centrophenoxine (Lucidril brand or generic equivalents) is available in jurisdictions where the compound is registered (France, Germany, Hungary, Austria, Japan, parts of Latin America). Pharmaceutical-grade material is supplied as 250 mg or 500 mg capsules or tablets as the hydrochloride salt.

Research-grade centrophenoxine hydrochloride is supplied by multiple chemical and pharmaceutical research suppliers (Sigma-Aldrich, Cayman Chemical, TCI America, MedChemExpress, Selleckchem, and others) at greater than 98 percent purity by HPLC. Supply is available in gram to kilogram quantities. Pricing is low, in the range of \$20 to \$80 per 100 grams of research-grade material, reflecting the straightforward synthesis and absence of stereocenters.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, ideally greater than 98 percent
- Mass spectrometry confirmation of molecular weight (258.08 plus or minus 0.01 for the protonated free base $[M+H]^+$, or 294.17 for the hydrochloride salt molecular ion)
- Nuclear magnetic resonance spectroscopy (proton and carbon-13) for structural confirmation
- Karl Fischer titration or loss-on-drying analysis for residual water content
- Residual solvent analysis (gas chromatography) for common synthesis solvents (dichloromethane, toluene, tetrahydrofuran, diethyl ether)

The centrophenoxine market is well established and the compound is not a frequent target of counterfeiting, but lot-to-lot variability in purity is observed across research-chemical suppliers. On-receipt analytical confirmation is appropriate for any investigation where dose-response precision is important.

9. Reconstitution and Handling

Centrophenoxine hydrochloride is freely soluble in water at room temperature (solubility exceeds 100 mg/mL). For research applications, the compound is typically supplied as a crystalline powder and reconstituted as needed.

Stock solution preparation: Aqueous stock solutions at 50 to 200 mg/mL in distilled water, phosphate-buffered saline, or normal saline are suitable for most research applications. For in vitro cell culture work, concentrated stock solutions at 100 to 500 mM in dimethyl sulfoxide (DMSO) may be prepared, with final DMSO concentration in the assay maintained below 0.1 percent to avoid solvent toxicity artifacts.

Storage of solid compound: Room temperature storage in a dry, tightly sealed container is adequate for the hydrochloride salt. Refrigerated storage (2 to 8 degrees Celsius) is recommended for long-term storage exceeding six months. The compound is not hygroscopic and does not require desiccant protection under normal laboratory humidity conditions.

Storage of solutions: Aqueous stock solutions should be stored at 2 to 8 degrees Celsius and used within 14 days of preparation. The ester bond is susceptible to hydrolysis in aqueous solution, particularly at elevated temperatures and at pH values above 8.0. Investigators requiring extended solution stability should prepare aliquots for single use and store frozen at minus 20 degrees Celsius; the compound is stable through at least five freeze-thaw cycles.

Light protection: Not strictly required, but light-protected storage is reasonable practice for solutions.

Oral dosing in research: For oral research dosing, the hydrochloride salt can be dissolved in water or juice for immediate consumption. The compound has a mildly bitter taste.

10. Stack Interactions and Combinations

Centrophenoxine interacts with several compound classes through its cholinergic precursor mechanism and through its metabolic profile. Investigators and research participants combining centrophenoxine with other compounds should consider the following interactions:

Racetams (piracetam, aniracetam, oxiracetam, pramiracetam): The combination of centrophenoxine with racetam-class compounds is one of the most extensively discussed nootropic stacks. Racetams are hypothesized to increase cholinergic neurotransmission demand by enhancing receptor sensitivity and turnover; centrophenoxine provides cholinergic precursor support to meet this increased demand [22, 24]. The combination has been studied preclinically: Bartus et al. (1981) demonstrated that piracetam combined with a choline source produced greater memory improvement in aged rats than either compound alone [24]. The rationale is that racetam-induced enhancement of cholinergic transmission depletes presynaptic acetylcholine stores; concurrent choline precursor supplementation prevents this depletion and the associated headache that is the most commonly reported adverse effect of racetam use without cholinergic support. Human clinical validation of this specific combination is absent.

Other cholinergic precursors (alpha-GPC, citicoline, choline bitartrate): Concurrent administration of centrophenoxine with other cholinergic precursors produces additive effects on brain choline availability and acetylcholine synthesis. The combination may be useful for maximizing cholinergic support but increases the risk of cholinergic adverse effects (gastrointestinal discomfort, excessive salivation, muscle tension). Dose adjustment of both compounds is advisable when combining.

Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine, huperzine A): Concurrent administration produces additive cholinergic effects through complementary mechanisms (increased acetylcholine synthesis plus decreased acetylcholine degradation). The combination is pharmacologically rational but increases the risk of cholinergic excess (nausea, diarrhea, bradycardia). Caution and dose titration are warranted.

Anticholinergic agents: Concurrent anticholinergic drugs (diphenhydramine, scopolamine, tricyclic antidepressants, older-generation antipsychotics) pharmacologically oppose the cholinergic activity of centrophenoxine and reduce its cognitive effects. The combination is generally counterproductive.

Antioxidant compounds (vitamin E, vitamin C, N-acetyl cysteine, alpha-lipoic acid): Additive antioxidant effects with no characterized adverse interactions. The combination may potentiate the lipofuscin-clearing and neuroprotective activities of centrophenoxine.

Serotonergic agents: No characterized pharmacokinetic or pharmacodynamic interactions. Centrophenoxine does not have significant serotonergic activity.

Central nervous system stimulants (caffeine, modafinil, amphetamines): No characterized pharmacokinetic interactions. The cholinergic and metabolic stimulatory effects of centrophenoxine may produce additive arousal effects with concurrent stimulant use; insomnia risk may be increased.

11. Adverse Events and Safety

11.1 Common adverse events

The adverse-event profile of centrophenoxine at therapeutic doses is favorable. The most commonly reported effects include:

- Gastrointestinal discomfort (nausea, stomach pain, mild diarrhea; 5 to 10 percent at therapeutic doses)
- Insomnia (3 to 8 percent; more common at higher doses and with evening administration)
- Headache (2 to 5 percent)
- Restlessness and anxiety (1 to 3 percent)
- Muscle tension (rare; reported at higher doses)
- Dizziness (rare)

These adverse events are dose-dependent, generally mild, and typically resolve with dose reduction. The gastrointestinal effects are attributed to peripheral cholinergic stimulation. The insomnia is attributed to the central arousal-promoting effects of enhanced cholinergic and metabolic activity.

11.2 Rare and serious adverse events

Serious adverse events are uncommon and poorly documented in the clinical literature. The following have been reported in individual cases or small series:

- Depression (reported at high doses; attributed to cholinergic excess affecting mood-regulatory circuits)
- Muscle tremor (reported at high doses; attributed to cholinergic overstimulation of motor pathways)
- Exacerbation of seizure disorders (theoretical concern due to cholinergic modulation of seizure threshold; not confirmed in controlled studies but listed as a caution)

11.3 Teratogenicity

DMAE and compounds that release DMAE (including centrophenoxine) have been associated with teratogenic effects in animal studies. The mechanism is attributed to disruption of choline metabolism during embryonic neural tube development. Centrophenoxine is contraindicated in pregnancy and in women planning pregnancy. This contraindication applies to DMAE-containing supplements as well.

11.4 Population cautions

The following populations should exercise caution or avoid centrophenoxine:

- Pregnant and breastfeeding women (contraindicated; teratogenic potential of DMAE)
- Individuals with major depression (cholinergic excess may worsen depressive symptoms)
- Individuals with seizure disorders (theoretical risk of reduced seizure threshold)
- Individuals with bipolar disorder (cholinergic excess may destabilize mood)
- Individuals with Parkinson's disease (the relationship between cholinergic tone and dopaminergic balance in Parkinson's disease is complex; excess cholinergic stimulation may worsen motor symptoms)

11.5 Overdose

No fatalities have been reported from centrophenoxine overdose. Symptoms of overdose are expected to reflect cholinergic excess: nausea, vomiting, diarrhea, excessive salivation, muscle fasciculation, and potentially bradycardia. Management is supportive with particular attention to cardiovascular monitoring.

11.6 Long-term safety

The compound has been in clinical use for over six decades. No long-term toxicity signal has emerged from postmarketing surveillance in jurisdictions where the compound is registered. The chronic tolerability is supported by the Fulop et al. (1990) nine-month trial, in which adverse-event rates in the centrophenoxine group were similar to placebo [15].

12. Comparative Assessment

This section presents a structured comparative assessment of five cholinergic, neuroprotective, or cognitive-enhancement compounds against centrophenoxine, evaluated against five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile, and overall validation. The five comparators were selected as the principal compounds that share mechanistic overlap with centrophenoxine or that occupy the same research-clinical space of cholinergic precursors and neuroprotective agents for age-related cognitive decline.

12.1 Alpha-glycerylphosphorylcholine (Alpha-GPC)

Mechanism: Alpha-GPC is a natural choline compound and a direct cholinergic precursor. Oral administration delivers choline across the blood-brain barrier through a specific transporter. Choline is then converted to acetylcholine by choline acetyltransferase. Alpha-GPC also contributes to membrane phospholipid synthesis through the Kennedy pathway [25].

Clinical evidence: Multiple clinical trials have evaluated alpha-GPC in vascular dementia, Alzheimer's disease, and stroke recovery. A meta-analysis by Traini et al. (2013) concluded that alpha-GPC produces modest but significant cognitive improvement in patients with dementia or cognitive impairment across multiple studies [25]. Effect sizes are generally small to moderate. The compound is marketed in Europe (Gliatilin, Delecit) and is widely available as a dietary supplement.

Novelty: Low. The cholinergic precursor mechanism is well established.

Effect size: Small to moderate in clinical trials in dementia populations. Larger than centrophenoxine in some head-to-head comparisons, attributable to the more direct and potent choline delivery mechanism.

Promising potential: Moderate. Widely available, well-tolerated, and supported by a larger clinical evidence base than centrophenoxine. Not in active development for new indications.

Side-effect profile: Favorable. The most common adverse effects are gastrointestinal (heartburn, nausea) and headache. Overall tolerability is similar to centrophenoxine.

Overall validation: Moderate to high. The clinical evidence base is more extensive than centrophenoxine's and includes larger trials and meta-analyses.

Comparison to centrophenoxine: Alpha-GPC is a more potent and more direct cholinergic precursor than centrophenoxine. Centrophenoxine has the distinctive advantage of lipofuscin-clearing and antioxidant activities that alpha-GPC does not possess. For cholinergic precursor support alone, alpha-GPC is generally preferred; for combined cholinergic and neuroprotective activity, centrophenoxine has a unique profile.

12.2 Citicoline (CDP-choline)

Mechanism: Citicoline (cytidine-5-diphosphocholine) is an endogenous nucleotide that serves as an intermediate in the Kennedy pathway for phosphatidylcholine synthesis. Oral citicoline is hydrolyzed to cytidine and choline in the gut, absorbed, and re-synthesized to citicoline in the brain. The choline supports acetylcholine synthesis; the cytidine is converted to uridine, which stimulates membrane phospholipid synthesis independently of the choline pathway [26].

Clinical evidence: Citicoline has been evaluated in large clinical trials for stroke recovery, traumatic brain injury, vascular dementia, and age-related cognitive decline. The ICTUS trial (2,298 patients) did not demonstrate benefit in acute ischemic stroke, though post-hoc subgroup analyses suggested benefit in older patients with moderate stroke severity [27]. Smaller trials in cognitive decline and dementia have reported positive results. The clinical evidence base is substantially larger than centrophenoxine's.

Novelty: Low. The nucleotide-based cholinergic and membrane support mechanism is well characterized.

Effect size: Variable. Positive in smaller trials for cognitive impairment; null in the large ICTUS stroke trial. The overall effect-size literature is mixed.

Promising potential: Moderate. Widely available as a dietary supplement and as a prescription medicine in some jurisdictions. Active ongoing research in traumatic brain injury and glaucoma.

Side-effect profile: Excellent. Citicoline is one of the best-tolerated cholinergic agents, with minimal adverse events even at high doses (up to 2000 mg/day).

Overall validation: Moderate to high. Extensive clinical literature, though the ICTUS trial result tempered enthusiasm.

Comparison to centrophenoxine: Citicoline delivers both choline and uridine (a dual-mechanism advantage), has a more extensive clinical evidence base, and is better tolerated at higher doses. Centrophenoxine retains the unique advantage of lipofuscin clearance and antioxidant membrane incorporation.

12.3 DMAE (dimethylaminoethanol, deanol)

Mechanism: DMAE is the immediate cholinergic precursor released by centrophenoxine hydrolysis. Free DMAE is methylated to choline and supports acetylcholine synthesis. It is incorporated into membrane phospholipids as phosphatidyl-DMAE. The mechanisms are identical to those of the DMAE moiety of centrophenoxine [10].

Clinical evidence: DMAE was studied extensively in the 1960s through 1980s for attention deficit disorders, movement disorders (tardive dyskinesia), and cognitive decline. A Cochrane-style review concluded that the evidence for DMAE efficacy in any indication is insufficient [28]. The compound was marketed as Deaner (deanol acetamidobenzoate) but was withdrawn from the US market in 1983 when the FDA required new evidence of efficacy. Individual clinical trials have produced mixed results.

Novelty: Low. DMAE is the historical reference compound for this mechanism.

Effect size: Inconsistent across trials. No robust demonstration of cognitive enhancement in adequately powered studies.

Promising potential: Low. Development is terminated. The compound persists as a dietary supplement in some markets.

Side-effect profile: Similar to centrophenoxine, with the addition of a teratogenicity concern that led to product label restrictions. Elevated doses produce insomnia, headache, and muscle tension.

Overall validation: Low. The clinical evidence is inconsistent, and the compound has been withdrawn from pharmaceutical markets.

Comparison to centrophenoxine: Centrophenoxine was developed specifically to overcome the limitations of free DMAE (poor blood-brain barrier penetration, rapid peripheral metabolism). Centrophenoxine delivers DMAE to the brain more efficiently and in the same dose produces higher central concentrations. The pCPA carrier also confers additional pharmacological activity (lipophilicity-mediated membrane effects). For all research-clinical purposes, centrophenoxine is preferred over free DMAE.

12.4 Piracetam

Mechanism: Piracetam is the prototypical racetam nootropic. The mechanism is not fully characterized but includes modulation of neurotransmitter systems (cholinergic, glutamatergic), enhancement of membrane fluidity, improvement of cerebral microcirculation, and facilitation of interhemispheric communication through callosal transmission [24, 29].

Clinical evidence: Piracetam has been studied in over 100 clinical trials across indications including cognitive decline, stroke recovery, dyslexia, vertigo, and myoclonus. A Cochrane review of piracetam for dementia (Flicker and Grimley Evans, 2001) concluded that the compound produces a modest global improvement but that the evidence is insufficient to recommend clinical use [29]. Piracetam is marketed as a prescription medicine in many countries outside the United States.

Novelty: Low. Piracetam is the historical reference nootropic (introduced 1964).

Effect size: Small in meta-analyses of cognitive outcomes. Larger in specific indications (cortical myoclonus, post-stroke aphasia).

Promising potential: Low for cognitive indications. The compound is not in active development for new cognitive applications.

Side-effect profile: Excellent. Piracetam is exceptionally well tolerated, with minimal adverse events even at high doses (up to 24 g/day for myoclonus). The principal adverse effect is racetam-associated headache when choline intake is insufficient.

Overall validation: Moderate. Extensive clinical literature spanning five decades, but meta-analytic evidence for cognitive enhancement is weak.

Comparison to centrophenoxine: Piracetam and centrophenoxine are mechanistically complementary rather than competitive. Piracetam enhances cholinergic demand; centrophenoxine supplies cholinergic precursors. The combination is one of the most frequently used nootropic stacks. As single agents, piracetam has a more extensive clinical evidence base but weaker effect sizes for cognition; centrophenoxine has a smaller evidence base but the unique lipofuscin-clearing mechanism.

12.5 Idebenone

Mechanism: Idebenone is a synthetic short-chain benzoquinone structurally related to coenzyme Q10. It functions as an electron carrier in the mitochondrial electron transport chain, a free radical scavenger, and an inhibitor of lipid peroxidation. Unlike coenzyme Q10, idebenone can accept electrons from complex III and donate them to complex IV even when complex I is inhibited, a property that is therapeutically relevant in mitochondrial diseases [30].

Clinical evidence: Idebenone has been studied in Friedreich's ataxia (approved in the European Union as Raxone/Sovrima for Leber's hereditary optic neuropathy), Alzheimer's disease, and age-related cognitive decline. Clinical trials in Alzheimer's disease (Gutzmann and Hadler, 1998; Thal et al., 2003) produced mixed results: the Gutzmann study reported significant cognitive improvement, while the larger Thal study was negative [30, 31]. The compound is marketed in Japan for Alzheimer's disease (Avan) and in some European jurisdictions for mitochondrial diseases.

Novelty: Moderate. The mitochondrial electron carrier mechanism is distinct from the cholinergic precursor mechanism of centrophenoxine.

Effect size: Mixed. Positive in some Alzheimer's trials and in Leber's hereditary optic neuropathy; negative in the largest Alzheimer's trial.

Promising potential: Moderate. Active development in mitochondrial diseases. Cognitive applications are deprioritized.

Side-effect profile: Favorable. The most common adverse effects are gastrointestinal (nausea, diarrhea) and are generally mild.

Overall validation: Moderate. More extensive clinical development than centrophenoxine in specific indications (mitochondrial disease), but the cognitive enhancement evidence is similarly mixed.

Comparison to centrophenoxine: Idebenone and centrophenoxine are mechanistically distinct neuroprotective agents. Idebenone targets mitochondrial electron transport and membrane lipid peroxidation; centrophenoxine targets cholinergic precursor supply, membrane phospholipid remodeling, and lipofuscin clearance. The two compounds could be complementary in a combined neuroprotective strategy, though this combination has not been studied. For cognitive enhancement in the elderly, neither compound has produced robust clinical evidence, but centrophenoxine's lipofuscin-clearing activity represents a unique mechanism that idebenone does not address.

12.6 Comparator summary

The five comparators occupy distinct positions in the cholinergic and neuroprotective pharmacology space. **Alpha-GPC** is the most potent direct cholinergic precursor with the strongest clinical evidence for cognitive benefit in dementia populations. **Citicoline** provides dual choline and uridine support with excellent tolerability and an extensive clinical evidence base. **DMAE** is the immediate metabolite of centrophenoxine with inferior pharmacokinetic properties; centrophenoxine is preferred over free DMAE for all applications. **Piracetam** is mechanistically complementary to centrophenoxine and is commonly combined with it; the two compounds address different aspects of cognitive pharmacology. **Idebenone** is a mitochondrial neuroprotective agent with a different mechanism and a different clinical trajectory.

Centrophenoxine occupies a unique position in this comparator landscape: it is the only compound with demonstrated lipofuscin-clearing activity in postmitotic neurons, a property that is not replicated by any of the comparators and that addresses a specific pathological feature of cellular aging. The compound's cholinergic precursor activity is less potent than alpha-GPC or citicoline, and its clinical evidence base is smaller than that of any of the comparators except DMAE. However, the composite pharmacological profile (cholinergic precursor plus lipofuscin clearance plus membrane phospholipid remodeling plus antioxidant activity) is unique and supports the compound's continued investigation as a multimechanistic neuroprotective agent for age-related cognitive decline. The compound is best positioned not as a first-line cholinergic supplement (for which alpha-GPC or citicoline are preferred) but as a complementary agent whose lipofuscin-clearing and antioxidant properties add a dimension of neuroprotection not available from the cholinergic precursors alone.

13. References

1. Nandy K, Bourne GH. Effect of centrophenoxine on the lipofuscin pigments in the neurones of senile guinea-pigs. *Nature*. 1966;210(5033):313-314.
2. Nandy K. Further studies on the effects of centrophenoxine on the lipofuscin pigment in the neurons of senile guinea-pigs. *J Gerontol*. 1968;23(1):82-92.
3. Zs-Nagy I. A survey of the available data on a new nootropic drug, BCE-001 (meclofenoxate). *Ann N Y Acad Sci*. 1994;717:102-114.
4. Zs-Nagy I, Semsei I. Centrophenoxine increases the rates of total and mRNA synthesis in the brain cortex of old rats: an explanation of its action in terms of the membrane hypothesis of aging. *Exp Gerontol*. 1984;19(3):171-178.
5. Marcer D, Hopkins SM. The differential effects of meclofenoxate on memory loss in the elderly. *Age Ageing*. 1977;6(2):123-131.
6. Pek G, Fulop T. Double-blind study with centrophenoxine in patients suffering from organic dementia. *Arch Gerontol Geriatr*. 1983;2(1-2):145-150.
7. Thuillier J, Rumpf P. Centrophenoxine: pharmacological properties of a new dimethylaminoethanol derivative. *Therapie*. 1961;16:101-113.
8. Marcer D. Centrophenoxine: a review of its pharmacological and clinical properties. *Curr Med Res Opin*. 1977;5(2):101-108.
9. Pharmaceutical synthesis literature. General esterification of 4-chlorophenoxyacetic acid with 2-(dimethylamino)ethanol. *Standard organic chemistry methodology*.
10. Haubrich DR, Gerber NH, Pflueger AB. Deanol affects choline metabolism in peripheral tissues of mice. *J Neurochem*. 1981;37(2):476-482.
11. Riga S, Riga D. Effects of centrophenoxine on the lipofuscin pigments in the nervous system of old rats. *Brain Res*. 1974;72(2):265-275.
12. Spoerri PE, Glees P. The effect of centrophenoxine on lipofuscin in the ageing rat hippocampus. *Exp Gerontol*. 1974;9(5):255-262.

13. Nehru B, Bhatt S. Centrophenoxine attenuates oxidative stress and cognitive dysfunction in aluminium exposed rats. *Indian J Exp Biol.* 2006;44(11):917-924.
14. Sharma D, Singh R. Centrophenoxine activates antioxidant enzymes in aged rat brain. *Indian J Exp Biol.* 1996;34(9):895-897.
15. Fulop T, Worum I, Csongor J, et al. Effects of centrophenoxine on body composition and some biochemical parameters of demented elderly people as revealed in a double-blind clinical trial. *Arch Gerontol Geriatr.* 1990;10(3):239-251.
16. Patro IK, Sharma SP, Bhattacharya S. Lipofuscin response to centrophenoxine in rat retinal pigment epithelium and frontal cortex. *Neurobiol Aging.* 1992;13(3):365-370.
17. Gedye JL, Exton-Smith AN, Wedgwood J. A method for measuring mental performance in the elderly and its use in a pilot clinical trial of meclofenoxate in organic dementia. *Age Ageing.* 1972;1(2):74-80.
18. Dolan SB, Gatch MB, Forster MJ, et al. The unapproved drug centrophenoxine (meclofenoxate) in cognitive enhancement dietary supplements. *Clin Toxicol.* 2022;60(10):1152-1158.
19. Luo Y, Bhatt S. Centrophenoxine attenuates cognitive deficits and oxidative stress in rats following chronic cerebral hypoperfusion. *Neurochem Res.* 2005;30(11):1473-1479.
20. Zs-Nagy I, Semsei I. Centrophenoxine increases the rates of total and mRNA synthesis in the brain cortex of old rats. *Exp Gerontol.* 1984;19(3):171-178.
21. Katz ML, Robison WG, Herrmann RK, et al. Lipofuscinogenesis in mice early treated with centrophenoxine. *Mech Ageing Dev.* 1983;22(3-4):237-243.
22. Saletu B, Grunberger J, Linzmayer L. Comparative neurophysiological study of the nootropic drugs piracetam and centrophenoxine. *Neuropsychobiology.* 1988;19(3):157-166.
23. Dastoor DP, Cole MG. Centrophenoxine in Alzheimer's disease. *Can J Psychiatry.* 1980;25(2):167-170.
24. Bartus RT, Dean RL, Sherman KA, et al. Profound effects of combining choline and piracetam on memory enhancement and cholinergic function in aged rats. *Neurobiol Aging.* 1981;2(2):105-111.

25. Traini E, Bramanti V, Amenta F. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline-containing phospholipid with a still interesting profile as cognition enhancing agent. *Curr Alzheimer Res.* 2013;10(10):1070-1079.
26. Secades JJ. Citicoline: pharmacological and clinical review, 2010 update. *Rev Neurol.* 2011;52(Suppl 2):S1-S62.
27. Davalos A, Alvarez-Sabin J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). *Lancet.* 2012;380(9839):349-357.
28. Deanol (DMAE) withdrawn from the US market. *FDA Drug Bulletin.* 1983.
29. Flicker L, Grimley Evans J. Piracetam for dementia or cognitive impairment. *Cochrane Database Syst Rev.* 2001;(2):CD001011.
30. Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. *J Neural Transm Suppl.* 1998;54:301-310.
31. Thal LJ, Grundman M, Berg J, et al. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. *Neurology.* 2003;61(11):1498-1502.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. Centrophenoxine is not approved by the United States Food and Drug Administration. The compound is registered as a medicine in several European and Asian jurisdictions; investigators should consult their local regulatory authority before any human research application.